Unsuccessful developing lung cancer drugs in the U.S. 1998-2014

Number of unsuccessful lung cancer drugs in the United States from 1998 to 2014

by Statista Research Department, last edited Oct 23, 2014
Unsuccessful developing lung cancer drugs in the U.S. 1998-2014 This statistic depicts the number of unsuccessful lung cancer drugs that were developed in the United States from 1998 to 2014. In 2011, there were 13 unsuccessfully developed lung cancer drugs. Since 1998, there have been 167 total medicines being developed for lung cancer that were discontinued, suspended, or had no development reported and 10 approved medications.
Show more

Number of unsuccessful lung cancer drugs in the United States from 1998 to 2014

You need to log in to download this statistic
Register for free
Already a member?
Log in
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield

Marlene Greenfield
Vice President, Hearst Magazines

Statistics on "Oncology"
  • Cancer facts
The most important statistics
  • Oncology market
  • Companies
  • Cancer drugs
  • Research and development
  • Immuno-oncology
  • Treatment types
  • Physicians and patients
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.